You are here

Article Text

Article menu

Download PDFPDF

XML
Hepatology
Aflatoxin B1 exposure and liver cirrhosis in Guatemala: a case–control study
  1. Christian S Alvarez1,
  2. Elisa Hernández2,
  3. Kira Escobar2,
  4. Carmen I Villagrán2,
  5. María F Kroker-Lobos3,
  6. Alvaro Rivera-Andrade3,
  7. Joshua W Smith4,
  8. Patricia A Egner4,
  9. Mariana Lazo5,6,
  10. Neal D Freedman1,
  11. Eliseo Guallar6,
  12. Michael Dean1,
  13. Barry I Graubard1,
  14. John D Groopman4,6,
  15. Manuel Ramírez-Zea3,
  16. Katherine A McGlynn1
  1. 1Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA
  2. 2Centro de Investigaciones Biomédicas, Facultad de Ciencias Médicas, Universidad de San Carlos de Guatemala, Guatemala, Guatemala
  3. 3INCAP Research Center for the Prevention of Chronic Diseases, Institute of Nutrition of Central America and Panama, Guatemala, Guatemala
  4. 4Department of Environmental Health and Engineering, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA
  5. 5Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
  6. 6Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA
  1. Correspondence to Dr Christian S Alvarez; christian.alvarez{at}nih.gov

Abstract

Objective In Guatemala, cirrhosis is among the 10 leading causes of death, and mortality rates have increased lately. The reasons for this heavy burden of disease are not clear as the prevalence of prominent risk factors, such as hepatitis B virus, hepatitis C virus and heavy alcohol consumption, appears to be low. Aflatoxin B1 (AFB1) exposure, however, appears to be high, and thus could be associated with the high burden of cirrhosis. Whether AFB1 increases the risk of cirrhosis in the absence of viral infection, however, is not clear.

Design Cirrhosis cases (n=100) from two major referral hospitals in Guatemala City were compared with controls (n=200) from a cross-sectional study. Logistic regression was used to estimate the ORs and 95% CIs of cirrhosis and quintiles of AFB1 in crude and adjusted models. A sex-stratified analysis was also conducted.

Results The median AFB1 level was significantly higher among the cases (11.4 pg/mg) than controls (5.11 pg/mg). In logistic regression analyses, higher levels of AFB1 was associated with cirrhosis (quintile 5 vs quintile 1, OR: 11.55; 95% CI 4.05 to 32.89). No attenuation was observed with adjustment by sex, ethnicity, hepatitis B virus status, and heavy alcohol consumption. A significantly increasing trend in association was observed in both models (p trend <0.01). Additionally, the cirrhosis–AFB1 association was more prominent among men.

Conclusions The current study found a significant positive association between AFB1 exposure and cirrhosis. Mitigation of AFB1 exposure and a better understanding of additional risk factors may be important to reduce the burden of cirrhosis in Guatemala.

  • liver cirrhosis
  • chronic liver disease
  • epidemiology
https://creativecommons.org/licenses/by/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

https://doi.org/10.1136/bmjgast-2020-000380

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Summary box

    What is already known about this subject?

    • Previous studies have reported an association between aflatoxin B1 (AFB1) and cirrhosis, particularly in populations with high prevalence of chronic infection with hepatitis B virus (HBV).

    • Whether AFB1 increases the risk of cirrhosis in the absence of viral infection, however, has not been well examined.

    What are the new findings?

    • In this case–control study, the median AFB1 level was significantly higher among the cases than controls.

    • Furthermore, there was a significantly increasing trend in the association between AFB1 and cirrhosis, even after adjustment with important covariates such as sex, ethnicity, HBV status, and heavy alcohol consumption.

    • In addition, the cirrhosis–AFB1 association was stronger among men than women.

    • To our knowledge, this is the first study to report an association between AFB1 and cirrhosis in Guatemala, a population with low prevalence of viral chronic hepatitis and low rate of heavy alcohol consumption.

    How might it impact on clinical practice in the foreseeable future?

    • Interventions to reduce exposure to AFB1 as well as effort to understand the role of other risk factors for cirrhosis may be important to reduce the burden of the disease in Guatemala.

    Introduction

    Aflatoxin B1 (AFB1) is a known risk factor for hepatocellular carcinoma (HCC),1 the dominant type of liver cancer. In Guatemala, the estimated incidence of HCC is the highest in the Western hemisphere.2 The major risk factors for HCC in Guatemala are not well characterised, but the prevalence of AFB1 exposure appears to be high.3 The great majority of HCCs (≥80%) develop in persons with pre-existing cirrhosis.4 Therefore, insights into the relationship between AFB1 and cirrhosis could be informative.

    With over one million deaths per year, cirrhosis is the 11th most common cause of death worldwide.5 In combination with HCC, cirrhosis accounts for 3.5% of all deaths globally.5 In Guatemala, cirrhosis is among the 10 leading causes of death and accounts for an estimated 3.4% of all premature deaths.6 In addition, mortality rates of cirrhosis have increased with an average annual per cent change of 14.4% over the past two decades,7 thus representing an important public health issue in Guatemala.

    Cirrhosis is a severe chronic liver disease which occurs in response to liver injury, featuring encapsulation or replacement of the damaged liver tissue by scar tissue with distortion of the hepatic vasculature and architecture.8 The disease is often asymptomatic until complications such as variceal bleeding, ascites and jaundice occur.9 In the USA, Europe and some countries in Latin America, cirrhosis is a leading indication for liver transplantation.10 11 HCC and cirrhosis are known to share common risk factors, including heavy alcohol consumption, hepatitis B virus (HBV), hepatitis C virus (HCV), and the related metabolic abnormalities of obesity and non-alcoholic fatty liver disease (NAFLD).12 It has also been reported that AFB1 is associated with cirrhosis among persons infected with HBV or HCV.13–15 Whether AFB1 increases the risk of cirrhosis in the absence of viral infection, however, remains unclear.

    In 2017, our group reported high levels of serum AFB1-albumin adducts and low prevalences of HBV (0.9%) and HCV (0.5%) infections in a cross-sectional study of Guatemalan adults.3 In addition, our group has found that the most important source of AFB1 exposure in the population was consumption of tortillas, a primary staple in the Guatemalan diet.16 This finding was consistent with prior evidence of high AFB1 levels in maize samples across the country.17 The current study was designed to assess the association between AFB1 and cirrhosis in Guatemala.

    Methods

    Study population

    One hundred cirrhosis cases were ascertained between February and November 2015 at two large public hospitals in Guatemala City (Hospital General San Juan de Dios and Hospital Roosevelt). The cases were outpatients recruited at the hospitals’ outpatient clinics and emergency rooms. Cirrhosis was diagnosed by abdominal ultrasonography using a quantitative scoring system, including morphological appearance of the liver surface, liver parenchymal texture, intrahepatic vascular structure and spleen size.

    Controls were selected from a cross-sectional study of Guatemalan adults, aged 40 years and older, that was conducted in 2016. The cross-sectional study enrolled 461 individuals from five departments of Guatemala in order to determine the prevalence of risk factors for liver cancer. The study recruitment was based on a non-random household visit using maps of the community when available. Details of the study have been previously described.3 The selection of 200 controls for the current study was based on the residence of the cirrhosis cases, 83% of whom resided in the department of Guatemala or vicinity. Hence, 85% of the controls were chosen from the departments of Guatemala and Escuintla (approximately 64 kilometers from the capital city). Individuals in the cross-sectional study who reported a history of cirrhosis were not eligible to be controls in the current analysis (n=7). A flow chart of the inclusion and exclusion criteria for cases and controls is presented in online supplementary figure S1.

    All cases and controls provided informed consent to participate.

    Data collection

    Study participants were interviewed by trained staff using a structured questionnaire that included information on sociodemographic characteristics (eg, age, sex, residence, ethnicity and occupation), alcohol and maize consumption, as well as use of medications. Study participants also donated blood samples which were used to determine hepatitis B surface antigen (HBsAg), antibody to hepatitis C virus (anti-HCV) and AFB1-lysine (AFB1-lys) adducts.

    AFB1-lysine adduct assessments

    The determination of AFB1-lys adduct levels was performed by isotope-dilution mass spectrometry18 at Dr. John D Groopman’s laboratory at the Johns Hopkins University Bloomberg School of Public Health. Adduct concentrations (pg/AFB1-lys/mL serum) were normalised to total serum albumin and expressed as pg AFB1-lys adduct/mg albumin. Details of the laboratory methods have been previously described.3

    Study covariates

    The covariates used in the analysis included age, sex, ethnicity (indigenous vs not indigenous), residence (department of Guatemala and vicinity vs other departments), occupation (farmer vs other), heavy alcohol consumption (alcohol consumption ≥2 drinks for men or ≥1 drink for women per day in the last year, or report of a period in life where five or more drinks every day were consumed), HBsAg and anti-HCV.

    Statistical analysis

    Medians and IQRs were calculated for continuous variables, and percentages were used for categorical variables. To examine differences in the characteristics between cases and controls, t-tests or Wilcoxon rank-sum tests were used for continuous variables, and χ2 or exact tests were used for categorical variables. Additionally, median and IQR of AFB1 for each covariate were computed among the controls, and the differences in the median were assessed by the Wilcoxon rank-sum test. Unconditional logistic regression was used to calculate the ORs and 95% CIs for the association between cirrhosis and the serum AFB1-albumin adduct levels by quintiles. A dose–response relationship between cirrhosis and AFB1 was examined, and p trends were calculated by scoring (1–5) the quintiles and including the score as a continuous variable in unadjusted and adjusted models. The logistic model selection was based on two different approaches: a stepwise variable selection procedure and examining the change in the estimated ORs by adding covariates, yielding the following covariates for the final model: sex, ethnicity, HBV status, and heavy alcohol consumption. Interaction terms were added to the final model and significance was evaluated using the log rank test. Finally, stratified analysis by sex was performed because of a statistically significant interaction with sex. All statistical analyses were conducted using SAS V.9.4 software, and two-sided p values <0.05 were regarded as statistically significant without adjustment for multiple comparisons.

    Results

    Table 1 shows the characteristics of the study participants. The median age of the participants was 55 years (IQR: 48–63). Of the participants, 57% were women. The majority (85%) of individuals resided in the departments of Guatemala and vicinity. Cirrhosis cases were more likely to report heavy alcohol consumption (52%) than were the controls (4%) (p<0.01). The prevalence of HBsAg was low (2.7%) but was statistically higher in cases (7%) than controls (0.5%) (p<0.01). The prevalence of anti-HCV was low (1.3%), and there was no significant difference in prevalence between the cases (3%) and controls (0.5%) (p=0.11). The median AFB1 level was significantly higher among the cases (11.4 pg/mg) than among the controls (5.11 pg/mg) (p<0.01).

    View this table:
    Table 1

    Sociodemographic, clinical and other characteristics of individuals by cirrhosis status

    Table 2 depicts the median values of AFB1-lys adducts by sociodemographic and other characteristics among the controls. Indigenous persons had a significantly higher median AFB1-lys adduct levels than did non-indigenous persons (15.2 pg/mg vs 4.8 pg/mg, p<0.01). Similarly, individuals who resided outside the department of Guatemala and vicinity had a significantly higher median AFB1 -lys adduct level than did the individuals who lived in the department of Guatemala and vicinity (17.8 pg/mg vs 4.9 pg/mg, p<0.01). No differences in median AFB1-lys adduct levels were observed by age, sex, occupation, excessive alcohol consumption, body mass index or HBsAg and anti-HCV status.

    View this table:
    Table 2

    Median and IQR of AFB1 by covariates in the control group

    Table 3 shows the results of the logistic regression analysis for the association between cirrhosis and AFB1-lys adduct levels estimated as ORs. Higher levels of AFB1 -lys was statistically significant associated with cirrhosis. In the unadjusted analysis, the OR of quintile 5 versus quintile 1 of AFB1-lys adduct was 11.55 (95% CI 4.05 to 32.89), while in the adjusted analysis the OR comparing the highest quintile of AFB1-lys adduct with the lowest quintile was 12.41 (95% CI 3.23 to 47.74). In both models, there was a significantly increasing trend in the relationship with increasing quintile (p trend=0.001). Using a three-knot restricted linear cubic regression spline, ORs were similar to those of the quintile analysis (data not shown). In addition, adding interaction terms between AFB1-lys adducts and the covariates in the final model yielded only one statistically significant interaction, which was between AFB1-lys adducts and sex (p=0.01).

    View this table:
    Table 3

    Association of cirrhosis status by quintile of AFB1-lysine adduct levels

    The sex-specific analysis of the association between cirrhosis and AFB1-lys adducts is presented in table 4. For instance, among women, the adjusted OR comparing the highest quintile of AFB1 with the lowest quintile was 5.61 (95% CI 1.24 to 25.38), while among men the equivalent comparison had an adjusted OR of 9.64 (95% CI 1.21 to 76.94).

    View this table:
    Table 4

    Sex-specific association of cirrhosis status by quintile of AFB1-lysine adduct levels

    Discussion

    In the current study, cases had significantly higher levels of AFB1-lys adducts than did the controls. In addition, there was a statistically significantly increasing trend in the association (OR) between AFB1-lys adduct levels and cirrhosis that remained after adjustment for sex, ethnicity, HBV status and heavy alcohol consumption. In addition, evidence of effect modification by sex was observed, with the association between AFB1-lys adduct levels and cirrhosis being more pronounced among men than women.

    The results of the current study are consistent with other studies from Africa and Asia, where AFB1 exposure has historically been high. In The Gambia, a study found that probable exposure to AFB1 significantly increased the risk of cirrhosis and that HBV infection had a synergistic effect on the AFB1–cirrhosis association.19 Similarly, a study in Egypt reported a significantly higher proportion of AFB1 signature mutation in TP53 among persons with chronic liver disease compared with controls.20 A Turkish study also reported a significantly higher mean level of AFB1 among individuals with cirrhosis compared with controls .13 Similarly, a study in Taiwan found that high serum AFB1 levels were associated with advanced liver disease.14 In addition, a recent nested case–control study in Taiwan reported a dose–response association between AFB1-albumin adduct levels and cirrhosis.15

    Fewer studies have been reported from the Americas, and the results have not been consistent. A study in Mexico found that persons with cirrhosis had high urinary levels of AFB1 adducts.21 In Brazil, an autopsy study found an association between AFB1 residues and chronic liver diseases, including cirrhosis.22 In contrast, a US study reported that the AFB1 signature mutation in TP53 was not evident in the tissue of individuals with cirrhosis.23

    In the current study, the AFB1 biomarker used reflects the formation of mutagenic AFB1-DNA adducts, and the risk of liver carcinogenesis has been demonstrated to increase with the level of aflatoxin exposure.24 A mechanism underlying the possible development of cirrhosis induced by AFB1 is not clear. In animal studies, parenchymal changes in the liver caused by steatosis, such as liver cell damage, mononuclear cell infiltration and fibrosis, have been observed after administration of AFB1.25–31 Furthermore, a recent study has suggested that myofibroblast-like cells may be involved in fibrosis due to AFB1 exposure.31 Other studies have postulated similar mechanisms, including formation of DNA adducts, protein adducts, and lipid peroxidation.32 In addition, it has been suggested that AFB1 may act both as a procarcinogen to induce DNA damage and as a liver-damaging agent.15 Liver injury has also been shown in experimental animal studies to increase cytochrome p450 enzyme activity, which increases the activation of AFB1 and results in greater injury to the liver.33–35

    Sex difference in the prevalence of cirrhosis has been described in several studies. For example, a US population-based survey reported that cirrhosis was nearly seven times more common among men than women.36 The study also reported that 54% of the cases with cirrhosis were attributable to viral hepatitis, excessive alcohol consumption and diabetes,36 all of which have been reported to be more common in men than in women.37–39 In general, the prevalence and severity of NAFLD also appear to be higher in men compared with women.40 Sex differences in AFB1 levels and in the metabolism of AFB1 have also been observed in some studies. Our previous work in Guatemala found that men had significantly higher circulating levels of AFB1-lys adducts than women.3 Animal studies have shown that castration of male rats reduced the hepatic metabolism of AFB1 (approximately 50%),41 and have reported that male rats are more likely to develop AFB-induced glutathione-S-transferase-P-positive hepatocytes (a marker of preneoplastic foci) than do female rats.42 This evidence may help to explain the current finding of the AFB1–cirrhosis association being more pronounced among men than women.

    To our knowledge, this is the first study to assess the association between AFB1 and cirrhosis in Guatemala, a population with low prevalence of viral chronic hepatitis and a low rate of heavy alcohol consumption. The strengths of the current study include the use of a robust biomarker of AFB1 exposure and the use of a community-based control group that is representative of the underlying general population. In addition, the diagnoses of cirrhosis were determined by ultrasound. Although ultrasound is not the gold standard for diagnosing cirrhosis, it has been reported that the diagnostic accuracy of ultrasound in the detection of cirrhosis is clinically acceptable,43 with a sensitivity of 52%–69% and a specificity of 74%–89%.44

    Limitations of the current study include that the AFB1-lys biomarker levels were determined at a single point in time, which may not accurately reflect the cumulative AFB1 exposure over time. However, as maize is the most important staple in the Guatemalan diet, it is unlikely that dietary exposure varied greatly over time. In addition, lack of information on other factors among the cases, such as body size and clinical parameters, precluded the ability to examine their effects on the AFB1–cirrhosis relationship. As there was no significant relationship between body size and AFB1 among the controls, however, it is unlikely that body size would have an effect on the AFB1–cirrhosis relationship.

    In conclusion, the current study found that cirrhosis was associated with AFB1 in Guatemala, a country with a high burden of liver disease. Interventions to mitigate exposure to AFB1 as well as efforts to understand the role of other risk factors for cirrhosis may be important to reduce the burden of the disease in Guatemala.

    References

    1. ↵
      1. Wogan GN
      . Aflatoxins as risk factors for hepatocellular carcinoma in humans. Cancer Res 1992;52:2114s–8.pmid:http://www.ncbi.nlm.nih.gov/pubmed/1311989
      OpenUrlAbstract/FREE Full Text
    2. ↵
      1. Ferlay JEM,
      2. Lam F,
      3. Colombet M, et al
      . Global cancer Observatory: cancer today 2018.
    3. ↵
      1. Smith JW,
      2. Kroker-Lobos MF,
      3. Lazo M, et al
      . Aflatoxin and viral hepatitis exposures in Guatemala: molecular biomarkers reveal a unique profile of risk factors in a region of high liver cancer incidence. PLoS One 2017;12:e0189255.doi:10.1371/journal.pone.0189255pmid:http://www.ncbi.nlm.nih.gov/pubmed/29236788
      OpenUrlPubMed
    4. ↵
      1. Mittal S,
      2. El-Serag HB
      . Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol 2013;47 Suppl:S2–6.doi:10.1097/MCG.0b013e3182872f29pmid:http://www.ncbi.nlm.nih.gov/pubmed/23632345
      OpenUrlCrossRefPubMed
    5. ↵
      1. Asrani SK,
      2. Devarbhavi H,
      3. Eaton J, et al
      . Burden of liver diseases in the world. J Hepatol 2019;70:151–71.doi:10.1016/j.jhep.2018.09.014pmid:http://www.ncbi.nlm.nih.gov/pubmed/30266282
      OpenUrlCrossRefPubMed
    6. ↵
      1. Institute for Health Metrics and Evaluation -Guatemala country profile
      , 2019. Available: http://www.healthdata.org/guatemala [Accessed 2 Sep 2019].
    7. ↵
      1. Mokdad AA,
      2. Lopez AD,
      3. Shahraz S, et al
      . Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med 2014;12:145.doi:10.1186/s12916-014-0145-ypmid:http://www.ncbi.nlm.nih.gov/pubmed/25242656
      OpenUrlCrossRefPubMed
    8. ↵
      1. Schuppan D,
      2. Afdhal NH,
      3. cirrhosis L
      . Liver cirrhosis. Lancet 2008;371:838–51.doi:10.1016/S0140-6736(08)60383-9pmid:http://www.ncbi.nlm.nih.gov/pubmed/18328931
      OpenUrlCrossRefPubMedWeb of Science
    9. ↵
      1. Suk KT,
      2. Kim DJ
      . Staging of liver fibrosis or cirrhosis: the role of hepatic venous pressure gradient measurement. World J Hepatol 2015;7:607–15.doi:10.4254/wjh.v7.i3.607pmid:http://www.ncbi.nlm.nih.gov/pubmed/25848485
      OpenUrlPubMed
    10. ↵
      1. Stasi C,
      2. Silvestri C,
      3. Voller F, et al
      . Epidemiology of liver cirrhosis. J Clin Exp Hepatol 2015;5:272.doi:10.1016/j.jceh.2015.06.002pmid:http://www.ncbi.nlm.nih.gov/pubmed/26628848
      OpenUrlPubMed
    11. ↵
      1. Santos O,
      2. Londoño M,
      3. Marín J, et al
      . An experience of liver transplantation in Latin America: a medical center in Colombia. Colomb Med 2015;46:8–13.doi:10.25100/cm.v46i1.1400pmid:http://www.ncbi.nlm.nih.gov/pubmed/26019379
      OpenUrlPubMed
    12. ↵
      1. Wong MCS,
      2. Huang J
      . The growing burden of liver cirrhosis: implications for preventive measures. Hepatol Int 2018;12:201–3.doi:10.1007/s12072-018-9865-ypmid:http://www.ncbi.nlm.nih.gov/pubmed/29679258
      OpenUrlPubMed
    13. ↵
      1. Aydın M,
      2. Aydın S,
      3. Bacanlı M, et al
      . Aflatoxin levels in chronic hepatitis B patients with cirrhosis or hepatocellular carcinoma in Balıkesir, Turkey. J Viral Hepat 2015;22:926–35.doi:10.1111/jvh.12410pmid:http://www.ncbi.nlm.nih.gov/pubmed/25894298
      OpenUrlPubMed
    14. ↵
      1. Chen C-H,
      2. Wang M-H,
      3. Wang J-H, et al
      . Aflatoxin exposure and hepatitis C virus in advanced liver disease in a hepatitis C virus endemic area in Taiwan. Am J Trop Med Hyg 2007;77:747–52.doi:10.4269/ajtmh.2007.77.747pmid:http://www.ncbi.nlm.nih.gov/pubmed/17978082
      OpenUrlAbstract/FREE Full Text
    15. ↵
      1. Chu Y-J,
      2. Yang H-I,
      3. Wu H-C, et al
      . Aflatoxin B1 exposure increases the risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis B virus carriers. Int J Cancer 2017;141:711–20.doi:10.1002/ijc.30782pmid:http://www.ncbi.nlm.nih.gov/pubmed/28509392
      OpenUrlPubMed
    16. ↵
      1. Kroker-Lobos MF,
      2. Alvarez CS,
      3. Rivera-Andrade A, et al
      . Association between aflatoxin-albumin adduct levels and tortilla consumption in Guatemalan adults. Toxicol Rep 2019;6:465–71.doi:10.1016/j.toxrep.2019.05.009pmid:http://www.ncbi.nlm.nih.gov/pubmed/31193789
      OpenUrlPubMed
    17. ↵
      1. Torres O,
      2. Matute J,
      3. Gelineau-van Waes J, et al
      . Human health implications from co-exposure to aflatoxins and fumonisins in maize-based foods in Latin America: Guatemala as a case study. World Mycotoxin J 2015;8:143–59.doi:10.3920/WMJ2014.1736
      OpenUrl
    18. ↵
      1. McCoy LF,
      2. Scholl PF,
      3. Schleicher RL, et al
      . Analysis of aflatoxin B1-lysine adduct in serum using isotope-dilution liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2005;19:2203–10.doi:10.1002/rcm.2045pmid:http://www.ncbi.nlm.nih.gov/pubmed/16015671
      OpenUrlCrossRefPubMed
    19. ↵
      1. Kuniholm MH,
      2. Lesi OA,
      3. Mendy M, et al
      . Aflatoxin exposure and viral hepatitis in the etiology of liver cirrhosis in the Gambia, West Africa. Environ Health Perspect 2008;116:1553–7.doi:10.1289/ehp.11661pmid:http://www.ncbi.nlm.nih.gov/pubmed/19057710
      OpenUrlPubMedWeb of Science
    20. ↵
      1. Hosny G,
      2. Farahat N,
      3. Tayel H, et al
      . Ser-249 TP53 and CTNNB1 mutations in circulating free DNA of Egyptian patients with hepatocellular carcinoma versus chronic liver diseases. Cancer Lett 2008;264:201–8.doi:10.1016/j.canlet.2008.01.031pmid:http://www.ncbi.nlm.nih.gov/pubmed/18313840
      OpenUrlPubMed
    21. ↵
      1. Alvarez-Banuelos M,
      2. Carvajal-Moreno M,
      3. Mendez-Ramirez I, et al
      . Free and DNA adducted aflatoxins in chronic liver diseases that predispose patients to hepatocellular carcinoma in Mexico. J Cancer Sci Ther 2015;7:274–82.
      OpenUrl
    22. ↵
      1. Ramalho LNZ,
      2. Porta LD,
      3. Rosim RE, et al
      . Aflatoxin B1 residues in human livers and their relationship with markers of hepatic carcinogenesis in São Paulo, Brazil. Toxicol Rep 2018;5:777–84.doi:10.1016/j.toxrep.2018.07.005pmid:http://www.ncbi.nlm.nih.gov/pubmed/30101081
      OpenUrlPubMed
    23. ↵
      1. Jiao J,
      2. Niu W,
      3. Wang Y, et al
      . Prevalence of Aflatoxin-Associated TP53R249S Mutation in Hepatocellular Carcinoma in Hispanics in South Texas. Cancer Prev Res 2018;11:103–12.doi:10.1158/1940-6207.CAPR-17-0235-ATpmid:http://www.ncbi.nlm.nih.gov/pubmed/29089331
      OpenUrlAbstract/FREE Full Text
    24. ↵
      1. Wild CP,
      2. Miller JD,
      3. Groopman JD
      . Mycotoxin control in low- and middle-income countries. Lyon (Fr: International agency for research on cancer, 2015.
    25. ↵
      1. Rosmael J
      . Are aflatoxins a cause of parenchymal liver disease in humans? University of Oslo 2016.
    26. ↵
      1. Karaman M,
      2. Ozen H,
      3. Tuzcu M, et al
      . Pathological, biochemical and haematological investigations on the protective effect of alpha-lipoic acid in experimental aflatoxin toxicosis in chicks. Br Poult Sci 2010;51:132–41.doi:10.1080/00071660903401839pmid:http://www.ncbi.nlm.nih.gov/pubmed/20390578
      OpenUrlCrossRefPubMed
    27. ↵
      1. Seffner W,
      2. Schiller F,
      3. Lippold U, et al
      . Experimental induction of liver fibrosis in young guinea pigs by combined application of copper sulphate and aflatoxin B1. Toxicol Lett 1997;92:161–72.doi:10.1016/S0378-4274(97)00052-0pmid:http://www.ncbi.nlm.nih.gov/pubmed/9334826
      OpenUrlPubMed
    28. ↵
      1. Wogan GN
      . Chemical nature and biological effects of the aflatoxins. Bacteriol Rev 1966;30:460–70.doi:10.1128/MMBR.30.2.460-470.1966pmid:http://www.ncbi.nlm.nih.gov/pubmed/5327461
      OpenUrlFREE Full Text
    29. ↵
      1. Ortatatli M,
      2. Oğuz H,
      3. Hatipoğlu F, et al
      . Evaluation of pathological changes in broilers during chronic aflatoxin (50 and 100 ppb) and clinoptilolite exposure. Res Vet Sci 2005;78:61–8.doi:10.1016/j.rvsc.2004.06.006pmid:http://www.ncbi.nlm.nih.gov/pubmed/15500841
      OpenUrlCrossRefPubMedWeb of Science
    30. ↵
      1. Wouters ATB,
      2. Casagrande RA,
      3. Wouters F, et al
      . An outbreak of aflatoxin poisoning in dogs associated with aflatoxin B1-contaminated maize products. J Vet Diagn Invest 2013;25:282–7.doi:10.1177/1040638713477409pmid:http://www.ncbi.nlm.nih.gov/pubmed/23417078
      OpenUrlCrossRefPubMed
    31. ↵
      1. Arana S,
      2. Alves VAF,
      3. Sabino M, et al
      . Immunohistochemical evidence for myofibroblast-like cells associated with liver injury induced by aflatoxin B1 in rainbow trout (Oncorhynchus mykiss). J Comp Pathol 2014;150:258–65.doi:10.1016/j.jcpa.2013.07.003pmid:http://www.ncbi.nlm.nih.gov/pubmed/24016778
      OpenUrlPubMed
    32. ↵
      1. Moudgil V,
      2. Redhu D,
      3. Dhanda S, et al
      . A review of molecular mechanisms in the development of hepatocellular carcinoma by aflatoxin and hepatitis B and C viruses. J Environ Pathol Toxicol Oncol 2013;32:165–75.doi:10.1615/JEnvironPatholToxicolOncol.2013007166pmid:http://www.ncbi.nlm.nih.gov/pubmed/24099430
      OpenUrlCrossRefPubMed
    33. ↵
      1. Kirby GM,
      2. Batist G,
      3. Alpert L, et al
      . Overexpression of cytochrome P-450 isoforms involved in aflatoxin B1 bioactivation in human liver with cirrhosis and hepatitis. Toxicol Pathol 1996;24:458–67.doi:10.1177/019262339602400408pmid:http://www.ncbi.nlm.nih.gov/pubmed/8864187
      OpenUrlCrossRefPubMedWeb of Science
    34. ↵
      1. Kirby GM,
      2. Chemin I,
      3. Montesano R, et al
      . Induction of specific cytochrome P450s involved in aflatoxin B1 metabolism in hepatitis B virus transgenic mice. Mol Carcinog 1994;11:74–80.doi:10.1002/mc.2940110204pmid:http://www.ncbi.nlm.nih.gov/pubmed/7916995
      OpenUrlCrossRefPubMedWeb of Science
    35. ↵
      1. Gemechu-Hatewu M,
      2. Platt KL,
      3. Oesch F, et al
      . Metabolic activation of aflatoxin B1 to aflatoxin B1-8,9-epoxide in woodchucks undergoing chronic active hepatitis. Int J Cancer 1997;73:587–91.doi:10.1002/(SICI)1097-0215(19971114)73:4&lt;587::AID-IJC21&gt;3.0.CO;2-5pmid:http://www.ncbi.nlm.nih.gov/pubmed/9389576
      OpenUrlCrossRefPubMedWeb of Science
    36. ↵
      1. Scaglione S,
      2. Kliethermes S,
      3. Cao G, et al
      . The epidemiology of cirrhosis in the United States: a population-based study. J Clin Gastroenterol 2015;49:690–6.doi:10.1097/MCG.0000000000000208pmid:http://www.ncbi.nlm.nih.gov/pubmed/25291348
      OpenUrlCrossRefPubMed
    37. ↵
      1. Kautzky-Willer A,
      2. Harreiter J,
      3. Pacini G
      . Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocr Rev 2016;37:278–316.doi:10.1210/er.2015-1137pmid:http://www.ncbi.nlm.nih.gov/pubmed/27159875
      OpenUrlCrossRefPubMed
    38. ↵
      1. Nolen-Hoeksema S
      . Gender differences in risk factors and consequences for alcohol use and problems. Clin Psychol Rev 2004;24:981–1010.doi:10.1016/j.cpr.2004.08.003pmid:http://www.ncbi.nlm.nih.gov/pubmed/15533281
      OpenUrlCrossRefPubMedWeb of Science
    39. ↵
      1. Wu EM,
      2. Wong LL,
      3. Hernandez BY, et al
      . Gender differences in hepatocellular cancer: disparities in nonalcoholic fatty liver disease/steatohepatitis and liver transplantation. Hepatoma Res 2018;4. doi:doi:10.20517/2394-5079.2018.87. [Epub ahead of print: 18 Oct 2018].pmid:http://www.ncbi.nlm.nih.gov/pubmed/30687780
    40. ↵
      1. Lonardo A,
      2. Nascimbeni F,
      3. Ballestri S, et al
      . Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology 2019;70:1457–69.doi:10.1002/hep.30626pmid:http://www.ncbi.nlm.nih.gov/pubmed/30924946
      OpenUrlCrossRefPubMed
    41. ↵
      1. Gurtoo HL,
      2. Motycka L
      . Effect of sex difference on the in vitro and in vivo metabolism of aflatoxin B1 by the rat. Cancer Res 1976;36:4663–71.pmid:http://www.ncbi.nlm.nih.gov/pubmed/1000509
      OpenUrlAbstract/FREE Full Text
    42. ↵
      1. Tsuji K,
      2. Gopalan P,
      3. Lehmann K, et al
      . Species and sex differences of aflatoxin B1-induced glutathione S-transferase placental form in single hepatocytes. Cancer Lett 1992;66:249–54.doi:10.1016/0304-3835(92)90254-Spmid:http://www.ncbi.nlm.nih.gov/pubmed/1451106
      OpenUrlCrossRefPubMedWeb of Science
    43. ↵
      1. Procopet B,
      2. Berzigotti A
      . Diagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsy. Gastroenterol Rep 2017;5:79–89.doi:10.1093/gastro/gox012pmid:http://www.ncbi.nlm.nih.gov/pubmed/28533906
      OpenUrlPubMed
    44. ↵
      1. Huber A,
      2. Ebner L,
      3. Heverhagen JT, et al
      . State-Of-The-Art imaging of liver fibrosis and cirrhosis: a comprehensive review of current applications and future perspectives. Eur J Radiol Open 2015;2:90–100.doi:10.1016/j.ejro.2015.05.002pmid:http://www.ncbi.nlm.nih.gov/pubmed/26937441
      OpenUrlPubMed

    Footnotes

    • Contributors Conceptualisation: EH, KE, CIV, CSA, KAM. Methodology: BIG, CSA, KAM. Formal analysis: CSA. Writing the original draft: CSA, KAM. Review and editing: ARA, MFKL, JWS, PE, ML, NF, EG, MD, JDG, MRZ.

    • Funding The study was funded by Dirección General de Investigación (DIGI), San Carlos University of Guatemala; the US National Institutes of Health (grants P30CA006973-52S3 and T32ES007141); and the Intramural Research Program of the National Cancer Institute, US National Institutes of Health.

    • Competing interests None declared.

    • Patient consent for publication Not required.

    • Ethics approval The cirrhosis study was approved by the institutional review boards of both public hospitals, and the cross-sectional study was approved by the institutional review boards of Johns Hopkins University Bloomberg School of Public Health and the Institute of Nutrition of Central America and Panama (INCAP).

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Data availability statement Data that support the findings of this study are available upon request from the authors.